Cellular Logistics

Executive Summary

Cellular Logistics is a preclinical-stage biotechnology company developing CFX™, a first-in-class therapeutic biomaterial derived from induced pluripotent stem cells (iPSCs). CFX™ is designed to be locally administered to prevent pathological ventricular remodeling after acute myocardial infarction (MI) and to remuscularize scarred myocardium in chronic heart failure when combined with therapeutic stem cells. The technology addresses a critical unmet need in cardiovascular disease, where current therapies fail to restore lost cardiac muscle. Based in Madison, Wisconsin, the company is advancing CFX™ through preclinical studies and positions its platform as a potential disease-modifying therapy for millions of heart failure patients worldwide. The company operates at the preclinical stage, with no disclosed funding rounds, and faces the typical risks of early-stage biotech, including manufacturing scale-up, regulatory pathway definition, and clinical validation. However, the novelty of iPSC-derived biomaterials and the large market opportunity in heart failure provide a compelling rationale for further development. Success in upcoming preclinical studies and securing partnerships or financing will be critical to advancing toward the clinic.

Upcoming Catalysts (preview)

• Q3 2026IND-enabling studies completion and filing for acute MI indication40% success
• H1 2026Series A financing round to support GMP manufacturing and IND-enabling work60% success
• Q4 2026Proof-of-concept preclinical data in chronic heart failure model50% success